BioSpace News Archive

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents

Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced the company’s U.S. 11,459,351 patent (the ‘351 patent) was granted by the U.S. Patent and Trademark Office.

October 19, 2022
·
5 min read
Business

Aligos Therapeutics to Announce Third Quarter Results November 2, 2022

Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”) today announced that it will report the company’s third quarter 2022 financial results on Wednesday, November 2, 2022 after the close of the U.S. financial markets.

October 19, 2022
·
2 min read
Policy

Intuitive becomes largest robotic-assisted surgery provider to be accredited by the Royal College of Surgeons of England

Intuitive announced that it has become the largest provider of robotic-assisted surgical technology training to be accredited by the Royal College of Surgeons of England.

October 19, 2022
·
2 min read
Biotech Bay

Tricida Announces $125 Million Debt Facility with Hercules Capital

Tricida, Inc. announced that it has entered into a debt facility with Hercules Capital, Inc., a leader in customizing debt financing for companies in the life sciences and technology-related markets.

October 19, 2022
·
4 min read
Business

Globus Medical Schedules Third Quarter Earnings 2022 Release and Conference Call

Globus Medical, Inc., a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2022 after the market close on Tuesday, November 8, 2022.

October 19, 2022
·
3 min read
Biotech Bay

Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanoma

Bristol Myers Squibb announced results from the Phase 3 CheckMate -76K trial, in which Opdivo as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo in patients with completely resected stage IIB or IIC melanoma.

October 19, 2022
·
43 min read
Biotech Bay

Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022

Vistagen Therapeutics, Inc. (Nasdaq: VTGN) (the Company) today announced results of voting and the partial adjournment of the Company’s 2022 Annual Meeting of Stockholders (the Annual Meeting) to Friday, October 28, 2022.

October 19, 2022
·
9 min read
Pharm Country

SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

Eagle Pharmaceuticals, Inc. announced that the Company will host an Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET.

October 19, 2022
·
1 min read
Business

Telix Reports Third Quarter 2022 Financial Results

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2022 (Q3 2022).

October 19, 2022
·
17 min read
Drug Development

Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine

Incyte (Nasdaq:INCY) today announced that data from the pivotal Phase 3 TRuE-V clinical trial program evaluating ruxolitinib cream (Opzelura™) 1.5% in patients 12 years of age and older with nonsegmental vitiligo have been published in The New England Journal of Medicine (NEJM).

October 19, 2022
·
16 min read